Scientists Develop New Treatment Option for Multidrug-Resistant Infections
Tebipenem pivoxil hydrobromide (SPR994)is a new carbapenem being developed by Spero Therapeutics that is being developed as an oral antimicrobial agent. Such a treatment may facilitate earlier discharge from hospital or the possibility of treating complex infections in the community.
Join the AMR Insights Ambassador Network today!
Connect to over 650 AMR professionals and students in 65 countries!